Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
|Articles|September 1, 2011
Potential cuts to medical programs leaves dermatologists uncertain about future
When the United States reached a virtual gridlock in July over raising the country's debt ceiling, most politicians agreed that the country needed to cut spending to bring the nation's budget back into line. With the medical component of the proposed spending cuts, On Call wondered how dermatologists viewed the political gymnastics occurring in Washington and how the impact on Medicare and Medicaid would affect their practices and medicine in the future.
Advertisement
Key Points
Both Democrats and Republicans seemed to focus on "entitlements," particularly Social Security, Medicare and Medicaid. It quickly became apparent, whether an agreement on the debt ceiling was reached or not, the future of those entitlements was going to remain on the table for negotiation.
With the medical component of the proposed spending cuts, On Call wondered how dermatologists viewed the political gymnastics occurring in Washington and how the impact on Medicare and Medicaid would affect their practices and medicine in the future.
Advertisement
Related to this article
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Advertisement
Advertisement
Trending on Dermatology Times
1
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
2
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
3
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5